全球充血性心力衰竭 (CHF) 藥物市場規模調查和預測：按類型、分銷渠道和地區分析，2022-2029 年

2021 年全球充血性心力衰竭治療市場價值約為 61.5 億美元，預計在 2022-2029 年預測期內將以超過 14.60% 的健康增長率增長。

充血性心力衰竭 (CHF) 是一種慢性健康狀況，會損害心臟的泵血能力並影響心肌的性能。 CHF 藥物是專門設計用於治療這種健康問題並有助於提高心臟有效泵血能力的藥物。 老年人口的增長、產品批准的增加以及醫療保健支出的增加等因素正在加強全球市場需求。

充血性心力衰竭 (CHF) 的發病率不斷增加，導致高發病率和死亡率，這引起了人們的極大關注。 全球健康數據交換登記處報告稱，充血性心力衰竭疾病的患病率估計在全球範圍內約佔 6434 萬例，2022 年美國有 550 萬例記錄在案。 因此，越來越多的充血性心力衰竭病例正在成為市場增長的催化劑。 此外，擴大藥物開發研發和強大的臨床藥物管道在預測期內提供了各種有利可圖的機會。 然而，市場上仿製藥和標籤外藥物的可用性以及新興國家報銷情況不佳將對整個 2022-2029 年預測期內的市場增長構成挑戰。

全球充血性心力衰竭治療市場研究中考慮的主要區域是亞太地區、北美、歐洲、拉丁美洲和世界其他地區。 由於患者意識的提高、政府舉措的增加和多項政策的實施，北美在收入方面佔據了市場主導地位。 另一方面，由於充血性心力衰竭患病率上升和醫療成本上升等因素，預計亞太地區在預測期內將以最高複合年增長率增長。

這項研究的目的是揭示近年來各個細分市場和國家/地區的市場規模，並預測未來幾年的市場規模。 該報告旨在捕捉被調查國家工業的定性和定量方面的情況。

它還提供了關鍵方面的詳細信息，例如決定市場未來增長的驅動因素和挑戰。 此外，它還包含了利益相關者投資的潛在微觀市場機會，以及對主要參與者和產品類型的競爭格局的深入分析。

內容

第 1 章執行摘要

• 市場概況
• 2019-2029 年各細分市場的全球市場估計和預測
  • 充血性心力衰竭藥物市場：按地區劃分，2019-2029 年
  • 充血性心力衰竭藥物市場（按類型）：2019-2029
  • 充血性心力衰竭藥物市場：按分銷渠道，2019-2029 年
• 主要趨勢
• 調查方法
• 調查先決條件

第 2 章充血性心力衰竭藥物的全球市場定義和範圍

• 調查的目的
• 市場定義和範圍
  • 調查範圍
  • 工業發展
• 調查年份
• 貨幣兌換率

第3章：全球充血性心力衰竭藥物市場動態

• 充血性心力衰竭藥物市場影響分析 (2019-2029)
  • 市場驅動因素
    • 充血性心力衰竭 (CHF) 患病率上升
    • 增加產品批准
  • 市場挑戰
    • 仿製藥和非適應症藥物在市場上的可用性
    • 新興國家/地區的贖回條件不佳
  • 市場機會
    • 增加藥物開發的研究和開發
    • 強大的臨床藥物管線

第四章全球充血性心力衰竭藥物市場產業分析

• 波特 5 力模型
  • 供應商的議價能力
  • 買家的議價能力
  • 新進入者的威脅
  • 替代品的威脅
  • 競爭公司之間的敵對關係
• 波特 5 力模型的未來方法 (2019-2029)
• 害蟲分析
  • 政治
  • 經濟的
  • 社交
  • 技術
• 頂級投資機會
• 關鍵成功策略
• 行業專家的展望
• 分析師的結論和建議

第 5 章風險評估：COVID-19 的影響

• 評估 COVID-19 對行業的總體影響
• COVID-19 之前和 COVID-19 之後的市場情景

第 6 章充血性心力衰竭藥物的全球市場，按類型

• 市場概況
• 全球充血性心力衰竭藥物市場：按類型劃分的表現 - 潛力分析
• 2019-2029 年按類型分列的充血性心力衰竭治療藥物全球市場估計和預測
• 充血性心力衰竭藥物市場、細分市場分析
  • ACE 抑製劑
  • 血管緊張素 2 受體拮抗劑
  • β受體阻滯劑
  • 利尿劑
  • 醛固酮拮抗劑
  • 強心劑
  • 其他

第 7 章。全球充血性心力衰竭藥物市場：按分銷渠道

• 市場概況
• 全球充血性心力衰竭藥物市場：按分銷渠道進行的性能潛力分析
• 2019-2029 年充血性心力衰竭藥物全球市場，按分銷渠道估計和預測
• 充血性心力衰竭藥物市場、細分市場分析
  • 醫院藥房
  • 零售藥房
  • 在線藥店

第 8 章充血性心力衰竭藥物的全球市場：區域分析

• 充血性心力衰竭藥物市場，按地區劃分的市場概況
• 北美
  • 美國
    • 按類型估算和預測，2019-2029 年
    • 2019-2029 年分銷渠道細分估計和預測
  • 加拿大
• 歐洲充血性心力衰竭藥物市場概況
  • 英國
  • 德國
  • 法國
  • 西班牙
  • 意大利
  • 其他歐洲地區
• 亞太充血性心力衰竭藥物市場概況
  • 中國
  • 印度
  • 日本
  • 澳大利亞
  • 韓國
  • 其他亞太地區
• 拉丁美洲充血性心力衰竭藥物市場概況
  • 巴西
  • 墨西哥
  • 其他拉丁美洲地區
• 世界其他地區

第 9 章衝突信息

• 頂級市場策略
• 公司簡介
  • 拜耳公司
    • 主要信息
    • 概覽
    • 財務信息（取決於數據可用性）
    • 產品概述
    • 近期趨勢
  • Novartis AG
  • Merck & Co., Inc.
  • AstraZeneca
  • Bristol-Myers Squibb Company
  • Amgen Inc.
  • Boehringer Ingelheim International GmbH
  • Pfizer, Inc.
  • Johnson & Johnson Services, Inc.
  • Otsuka Pharmaceutical Co., Ltd.

第 10 章研究過程

• 研究過程
  • 數據挖掘
  • 分析
  • 市場評估
  • 驗證
  • 出版
• 調查屬性
• 調查先決條件

Global Congestive Heart Failure Drugs Market is valued at approximately USD 6.15 billion in 2021 and is anticipated to grow with a healthy growth rate of more than 14.60% over the forecast period 2022-2029. Congestive heart failure (CHF) is a chronic health condition that reduces the pumping of blood in the heart and impacts the ability of the heart muscle. The CHF drugs are specially designed drugs that are used to cure this health problem and aid in increasing the ability of the heart to pump blood effectively. Factors such as the increasing geriatric population, rising product approvals, coupled with growing healthcare expenditure are reinforcing the market demand around the world.

The rising incidences of Congestive Heart Failure (CHF) is a major concern that leads to high morbidity and mortality rate. The Global Health Data Exchange registry reported that the prevalence of congestive heart failure disease was estimated to account for approximately around 64.34 million cases globally, and in the U.S., the incidences were recorded with 5.5 million in 2022. Therefore, the growing cases of CHF are acting as a catalyzing factor for market growth. In addition, the growing R&D for drug development, as well as the strong clinical drugs pipeline are offering various lucrative opportunities over the forecasting years. However, the availability of generic and off-label drugs in the market and poor reimbursement scenarios in developing countries are challenging the market growth throughout the forecast period of 2022-2029.

The key regions considered for the Global Congestive Heart Failure Drugs Market study include Asia Pacific, North America, Europe, Latin America, and the Rest of the World. North America dominated the market in terms of revenue, owing to the rise in patient awareness, along with the rising government initiatives and implementation of several policies. Whereas, the Asia Pacific is expected to grow with the highest CAGR during the forecast period, owing to factors such as the increasing prevalence of congestive heart failure, as well as rising healthcare expenditure in the regional market space.

Major market players included in this report are:

Bayer AG

Novartis AG

Merck & Co., Inc.

AstraZeneca

Bristol-Myers Squibb Company

Amgen Inc.

Boehringer Ingelheim International GmbH

Pfizer, Inc.

Johnson & Johnson Services, Inc.

Otsuka Pharmaceutical Co., Ltd.

Recent Developments in the Market:

• In February 2021, AstraZeneca declared the successful regulatory approval of Forxiga in China. The product has already received approval in the U.S., Europe, and Japan, which indicates heart failure with or without type-2 diabetes in adults.

Global Congestive Heart Failure Drugs Market Report Scope:

Historical Data: 2019-2020-2021

Base Year for Estimation: 2021

Forecast period: 2022-2029

Report Coverage: Revenue forecast, Company Ranking, Competitive Landscape, Growth factors, and Trends

Segments Covered: Type, Distribution Channel, Region

Regional Scope: North America; Europe; Asia Pacific; Latin America; Rest of the World

Customization Scope: Free report customization (equivalent up to 8 analyst's working hours) with purchase. Addition or alteration to country, regional & segment scope*

The objective of the study is to define market sizes of different segments & countries in recent years and to forecast the values to the coming years. The report is designed to incorporate both qualitative and quantitative aspects of the industry within countries involved in the study.

The report also caters detailed information about the crucial aspects such as driving factors & challenges which will define the future growth of the market. Additionally, it also incorporates potential opportunities in micro markets for stakeholders to invest along with the detailed analysis of competitive landscape and Type offerings of key players. The detailed segments and sub-segment of the market are explained below:

By Type:

ACE Inhibitors

Angiotensin 2 Receptor Blockers

Beta Blockers

Diuretics

Aldosterone Antagonists

Inotropes

Others

By Distribution Channel:

Hospital Pharmacies

Retail Pharmacies

Online Pharmacies

By Region:

North America

U.S.

Canada

Europe

UK

Germany

France

Spain

Italy

ROE

Asia Pacific

China

India

Japan

Australia

South Korea

RoAPAC

Latin America

Brazil

Mexico

RoLA

Rest of the World

Table of Contents

Chapter 1. Executive Summary

• 1.1. Market Snapshot
• 1.2. Global & Segmental Market Estimates & Forecasts, 2019-2029 (USD Billion)
  • 1.2.1. Congestive Heart Failure Drugs Market, by Region, 2019-2029 (USD Billion)
  • 1.2.2. Congestive Heart Failure Drugs Market, by Type, 2019-2029 (USD Billion)
  • 1.2.3. Congestive Heart Failure Drugs Market, by Distribution Channel, 2019-2029 (USD Billion)
• 1.3. Key Trends
• 1.4. Estimation Methodology
• 1.5. Research Assumption

Chapter 2. Global Congestive Heart Failure Drugs Market Definition and Scope

• 2.1. Objective of the Study
• 2.2. Market Definition & Scope
  • 2.2.1. Scope of the Study
  • 2.2.2. Industry Evolution
• 2.3. Years Considered for the Study
• 2.4. Currency Conversion Rates

Chapter 3. Global Congestive Heart Failure Drugs Market Dynamics

• 3.1. Congestive Heart Failure Drugs Market Impact Analysis (2019-2029)
  • 3.1.1. Market Drivers
    • 3.1.1.1. Rising incidences of Congestive heart failure (CHF)
    • 3.1.1.2. Increasing product approvals
  • 3.1.2. Market Challenges
    • 3.1.2.1. Availability of generic and off-label drugs in the market
    • 3.1.2.2. Poor reimbursement scenarios in developing countries
  • 3.1.3. Market Opportunities
    • 3.1.3.1. Growing R&D for drug development
    • 3.1.3.2. Strong clinical drugs pipeline

Chapter 4. Global Congestive Heart Failure Drugs Market Industry Analysis

• 4.1. Porter's 5 Force Model
  • 4.1.1. Bargaining Power of Suppliers
  • 4.1.2. Bargaining Power of Buyers
  • 4.1.3. Threat of New Entrants
  • 4.1.4. Threat of Substitutes
  • 4.1.5. Competitive Rivalry
• 4.2. Futuristic Approach to Porter's 5 Force Model (2019-2029)
• 4.3. PEST Analysis
  • 4.3.1. Political
  • 4.3.2. Economical
  • 4.3.3. Social
  • 4.3.4. Technological
• 4.4. Top investment opportunity
• 4.5. Top winning strategies
• 4.6. Industry Experts Prospective
• 4.7. Analyst Recommendation & Conclusion

Chapter 5. Risk Assessment: COVID-19 Impact

• 5.1. Assessment of the overall impact of COVID-19 on the industry
• 5.2. Pre COVID-19 and post COVID-19 Market scenario

Chapter 6. Global Congestive Heart Failure Drugs Market, by Type

• 6.1. Market Snapshot
• 6.2. Global Congestive Heart Failure Drugs Market by Type, Performance - Potential Analysis
• 6.3. Global Congestive Heart Failure Drugs Market Estimates & Forecasts by Type 2019-2029 (USD Billion)
• 6.4. Congestive Heart Failure Drugs Market, Sub Segment Analysis
  • 6.4.1. ACE Inhibitors
  • 6.4.2. Angiotensin 2 Receptor Blockers
  • 6.4.3. Beta Blockers
  • 6.4.4. Diuretics
  • 6.4.5. Aldosterone Antagonists
  • 6.4.6. Inotropes
  • 6.4.7. Others

Chapter 7. Global Congestive Heart Failure Drugs Market, by Distribution Channel

• 7.1. Market Snapshot
• 7.2. Global Congestive Heart Failure Drugs Market by Distribution Channel, Performance - Potential Analysis
• 7.3. Global Congestive Heart Failure Drugs Market Estimates & Forecasts by Distribution Channel 2019-2029 (USD Billion)
• 7.4. Congestive Heart Failure Drugs Market, Sub Segment Analysis
  • 7.4.1. Hospital Pharmacies
  • 7.4.2. Retail Pharmacies
  • 7.4.3. Online Pharmacies

Chapter 8. Global Congestive Heart Failure Drugs Market, Regional Analysis

• 8.1. Congestive Heart Failure Drugs Market, Regional Market Snapshot
• 8.2. North America Congestive Heart Failure Drugs Market
  • 8.2.1. U.S. Congestive Heart Failure Drugs Market
    • 8.2.1.1. Type breakdown estimates & forecasts, 2019-2029
    • 8.2.1.2. Distribution Channel breakdown estimates & forecasts, 2019-2029
  • 8.2.2. Canada Congestive Heart Failure Drugs Market
• 8.3. Europe Congestive Heart Failure Drugs Market Snapshot
  • 8.3.1. U.K. Congestive Heart Failure Drugs Market
  • 8.3.2. Germany Congestive Heart Failure Drugs Market
  • 8.3.3. France Congestive Heart Failure Drugs Market
  • 8.3.4. Spain Congestive Heart Failure Drugs Market
  • 8.3.5. Italy Congestive Heart Failure Drugs Market
  • 8.3.6. Rest of Europe Congestive Heart Failure Drugs Market
• 8.4. Asia-Pacific Congestive Heart Failure Drugs Market Snapshot
  • 8.4.1. China Congestive Heart Failure Drugs Market
  • 8.4.2. India Congestive Heart Failure Drugs Market
  • 8.4.3. Japan Congestive Heart Failure Drugs Market
  • 8.4.4. Australia Congestive Heart Failure Drugs Market
  • 8.4.5. South Korea Congestive Heart Failure Drugs Market
  • 8.4.6. Rest of Asia Pacific Congestive Heart Failure Drugs Market
• 8.5. Latin America Congestive Heart Failure Drugs Market Snapshot
  • 8.5.1. Brazil Congestive Heart Failure Drugs Market
  • 8.5.2. Mexico Congestive Heart Failure Drugs Market
  • 8.5.3. Rest of Latin America Congestive Heart Failure Drugs Market
• 8.6. Rest of The World Congestive Heart Failure Drugs Market

Chapter 9. Competitive Intelligence

• 9.1. Top Market Strategies
• 9.2. Company Profiles
  • 9.2.1. Bayer AG
    • 9.2.1.1. Key Information
    • 9.2.1.2. Overview
    • 9.2.1.3. Financial (Subject to Data Availability)
    • 9.2.1.4. Product Summary
    • 9.2.1.5. Recent Developments
  • 9.2.2. Novartis AG
  • 9.2.3. Merck & Co., Inc.
  • 9.2.4. AstraZeneca
  • 9.2.5. Bristol-Myers Squibb Company
  • 9.2.6. Amgen Inc.
  • 9.2.7. Boehringer Ingelheim International GmbH
  • 9.2.8. Pfizer, Inc.
  • 9.2.9. Johnson & Johnson Services, Inc.
  • 9.2.10. Otsuka Pharmaceutical Co., Ltd.

Chapter 10. Research Process

• 10.1. Research Process
  • 10.1.1. Data Mining
  • 10.1.2. Analysis
  • 10.1.3. Market Estimation
  • 10.1.4. Validation
  • 10.1.5. Publishing
• 10.2. Research Attributes
• 10.3. Research Assumption

LIST OF TABLES

• TABLE 1. Global Congestive Heart Failure Drugs Market, report scope
• TABLE 2. Global Congestive Heart Failure Drugs Market estimates & forecasts by Region 2019-2029 (USD Billion)
• TABLE 3. Global Congestive Heart Failure Drugs Market estimates & forecasts by Type 2019-2029 (USD Billion)
• TABLE 4. Global Congestive Heart Failure Drugs Market estimates & forecasts by Distribution Channel 2019-2029 (USD Billion)
• TABLE 5. Global Congestive Heart Failure Drugs Market by segment, estimates & forecasts, 2019-2029 (USD Billion)
• TABLE 6. Global Congestive Heart Failure Drugs Market by region, estimates & forecasts, 2019-2029 (USD Billion)
• TABLE 7. Global Congestive Heart Failure Drugs Market by segment, estimates & forecasts, 2019-2029 (USD Billion)
• TABLE 8. Global Congestive Heart Failure Drugs Market by region, estimates & forecasts, 2019-2029 (USD Billion)
• TABLE 9. Global Congestive Heart Failure Drugs Market by segment, estimates & forecasts, 2019-2029 (USD Billion)
• TABLE 10. Global Congestive Heart Failure Drugs Market by region, estimates & forecasts, 2019-2029 (USD Billion)
• TABLE 11. Global Congestive Heart Failure Drugs Market by segment, estimates & forecasts, 2019-2029 (USD Billion)
• TABLE 12. Global Congestive Heart Failure Drugs Market by region, estimates & forecasts, 2019-2029 (USD Billion)
• TABLE 13. Global Congestive Heart Failure Drugs Market by segment, estimates & forecasts, 2019-2029 (USD Billion)
• TABLE 14. Global Congestive Heart Failure Drugs Market by region, estimates & forecasts, 2019-2029 (USD Billion)
• TABLE 15. U.S. Congestive Heart Failure Drugs Market estimates & forecasts, 2019-2029 (USD Billion)
• TABLE 16. U.S. Congestive Heart Failure Drugs Market estimates & forecasts by segment 2019-2029 (USD Billion)
• TABLE 17. U.S. Congestive Heart Failure Drugs Market estimates & forecasts by segment 2019-2029 (USD Billion)
• TABLE 18. Canada Congestive Heart Failure Drugs Market estimates & forecasts, 2019-2029 (USD Billion)
• TABLE 19. Canada Congestive Heart Failure Drugs Market estimates & forecasts by segment 2019-2029 (USD Billion)
• TABLE 20. Canada Congestive Heart Failure Drugs Market estimates & forecasts by segment 2019-2029 (USD Billion)
• TABLE 21. UK Congestive Heart Failure Drugs Market estimates & forecasts, 2019-2029 (USD Billion)
• TABLE 22. UK Congestive Heart Failure Drugs Market estimates & forecasts by segment 2019-2029 (USD Billion)
• TABLE 23. UK Congestive Heart Failure Drugs Market estimates & forecasts by segment 2019-2029 (USD Billion)
• TABLE 24. Germany Congestive Heart Failure Drugs Market estimates & forecasts, 2019-2029 (USD Billion)
• TABLE 25. Germany Congestive Heart Failure Drugs Market estimates & forecasts by segment 2019-2029 (USD Billion)
• TABLE 26. Germany Congestive Heart Failure Drugs Market estimates & forecasts by segment 2019-2029 (USD Billion)
• TABLE 27. France Congestive Heart Failure Drugs Market estimates & forecasts, 2019-2029 (USD Billion)
• TABLE 28. France Congestive Heart Failure Drugs Market estimates & forecasts by segment 2019-2029 (USD Billion)
• TABLE 29. France Congestive Heart Failure Drugs Market estimates & forecasts by segment 2019-2029 (USD Billion)
• TABLE 30. Italy Congestive Heart Failure Drugs Market estimates & forecasts, 2019-2029 (USD Billion)
• TABLE 31. Italy Congestive Heart Failure Drugs Market estimates & forecasts by segment 2019-2029 (USD Billion)
• TABLE 32. Italy Congestive Heart Failure Drugs Market estimates & forecasts by segment 2019-2029 (USD Billion)
• TABLE 33. Spain Congestive Heart Failure Drugs Market estimates & forecasts, 2019-2029 (USD Billion)
• TABLE 34. Spain Congestive Heart Failure Drugs Market estimates & forecasts by segment 2019-2029 (USD Billion)
• TABLE 35. Spain Congestive Heart Failure Drugs Market estimates & forecasts by segment 2019-2029 (USD Billion)
• TABLE 36. RoE Congestive Heart Failure Drugs Market estimates & forecasts, 2019-2029 (USD Billion)
• TABLE 37. RoE Congestive Heart Failure Drugs Market estimates & forecasts by segment 2019-2029 (USD Billion)
• TABLE 38. RoE Congestive Heart Failure Drugs Market estimates & forecasts by segment 2019-2029 (USD Billion)
• TABLE 39. China Congestive Heart Failure Drugs Market estimates & forecasts, 2019-2029 (USD Billion)
• TABLE 40. China Congestive Heart Failure Drugs Market estimates & forecasts by segment 2019-2029 (USD Billion)
• TABLE 41. China Congestive Heart Failure Drugs Market estimates & forecasts by segment 2019-2029 (USD Billion)
• TABLE 42. India Congestive Heart Failure Drugs Market estimates & forecasts, 2019-2029 (USD Billion)
• TABLE 43. India Congestive Heart Failure Drugs Market estimates & forecasts by segment 2019-2029 (USD Billion)
• TABLE 44. India Congestive Heart Failure Drugs Market estimates & forecasts by segment 2019-2029 (USD Billion)
• TABLE 45. Japan Congestive Heart Failure Drugs Market estimates & forecasts, 2019-2029 (USD Billion)
• TABLE 46. Japan Congestive Heart Failure Drugs Market estimates & forecasts by segment 2019-2029 (USD Billion)
• TABLE 47. Japan Congestive Heart Failure Drugs Market estimates & forecasts by segment 2019-2029 (USD Billion)
• TABLE 48. South Korea Congestive Heart Failure Drugs Market estimates & forecasts, 2019-2029 (USD Billion)
• TABLE 49. South Korea Congestive Heart Failure Drugs Market estimates & forecasts by segment 2019-2029 (USD Billion)
• TABLE 50. South Korea Congestive Heart Failure Drugs Market estimates & forecasts by segment 2019-2029 (USD Billion)
• TABLE 51. Australia Congestive Heart Failure Drugs Market estimates & forecasts, 2019-2029 (USD Billion)
• TABLE 52. Australia Congestive Heart Failure Drugs Market estimates & forecasts by segment 2019-2029 (USD Billion)
• TABLE 53. Australia Congestive Heart Failure Drugs Market estimates & forecasts by segment 2019-2029 (USD Billion)
• TABLE 54. RoAPAC Congestive Heart Failure Drugs Market estimates & forecasts, 2019-2029 (USD Billion)
• TABLE 55. RoAPAC Congestive Heart Failure Drugs Market estimates & forecasts by segment 2019-2029 (USD Billion)
• TABLE 56. RoAPAC Congestive Heart Failure Drugs Market estimates & forecasts by segment 2019-2029 (USD Billion)
• TABLE 57. Brazil Congestive Heart Failure Drugs Market estimates & forecasts, 2019-2029 (USD Billion)
• TABLE 58. Brazil Congestive Heart Failure Drugs Market estimates & forecasts by segment 2019-2029 (USD Billion)
• TABLE 59. Brazil Congestive Heart Failure Drugs Market estimates & forecasts by segment 2019-2029 (USD Billion)
• TABLE 60. Mexico Congestive Heart Failure Drugs Market estimates & forecasts, 2019-2029 (USD Billion)
• TABLE 61. Mexico Congestive Heart Failure Drugs Market estimates & forecasts by segment 2019-2029 (USD Billion)
• TABLE 62. Mexico Congestive Heart Failure Drugs Market estimates & forecasts by segment 2019-2029 (USD Billion)
• TABLE 63. RoLA Congestive Heart Failure Drugs Market estimates & forecasts, 2019-2029 (USD Billion)
• TABLE 64. RoLA Congestive Heart Failure Drugs Market estimates & forecasts by segment 2019-2029 (USD Billion)
• TABLE 65. RoLA Congestive Heart Failure Drugs Market estimates & forecasts by segment 2019-2029 (USD Billion)
• TABLE 66. Row Congestive Heart Failure Drugs Market estimates & forecasts, 2019-2029 (USD Billion)
• TABLE 67. Row Congestive Heart Failure Drugs Market estimates & forecasts by segment 2019-2029 (USD Billion)
• TABLE 68. Row Congestive Heart Failure Drugs Market estimates & forecasts by segment 2019-2029 (USD Billion)
• TABLE 69. List of secondary sources, used in the study of global Congestive Heart Failure Drugs Market
• TABLE 70. List of primary sources, used in the study of global Congestive Heart Failure Drugs Market
• TABLE 71. Years considered for the study
• TABLE 72. Exchange rates considered

List of tables and figures and dummy in nature, final lists may vary in the final deliverable

LIST OF FIGURES

List of figures

• FIG 1. Global Congestive Heart Failure Drugs Market, research methodology
• FIG 2. Global Congestive Heart Failure Drugs Market, Market estimation techniques
• FIG 3. Global Market size estimates & forecast methods
• FIG 4. Global Congestive Heart Failure Drugs Market, key trends 2021
• FIG 5. Global Congestive Heart Failure Drugs Market, growth prospects 2022-2029
• FIG 6. Global Congestive Heart Failure Drugs Market, porters 5 force model
• FIG 7. Global Congestive Heart Failure Drugs Market, pest analysis
• FIG 8. Global Congestive Heart Failure Drugs Market, value chain analysis
• FIG 9. Global Congestive Heart Failure Drugs Market by segment, 2019 & 2029 (USD Billion)
• FIG 10. Global Congestive Heart Failure Drugs Market by segment, 2019 & 2029 (USD Billion)
• FIG 11. Global Congestive Heart Failure Drugs Market by segment, 2019 & 2029 (USD Billion)
• FIG 12. Global Congestive Heart Failure Drugs Market by segment, 2019 & 2029 (USD Billion)
• FIG 13. Global Congestive Heart Failure Drugs Market by segment, 2019 & 2029 (USD Billion)
• FIG 14. Global Congestive Heart Failure Drugs Market, regional snapshot 2019 & 2029
• FIG 15. North America Congestive Heart Failure Drugs Market 2019 & 2029 (USD Billion)
• FIG 16. Europe Congestive Heart Failure Drugs Market 2019 & 2029 (USD Billion)
• FIG 17. Asia Pacific Congestive Heart Failure Drugs Market 2019 & 2029 (USD Billion)
• FIG 18. Latin America Congestive Heart Failure Drugs Market 2019 & 2029 (USD Billion)
• FIG 19. Global Congestive Heart Failure Drugs Market, company Market share analysis (2021)

List of tables and figures and dummy in nature, final lists may vary in the final deliverable